Interestingly, our previous case-control study showed that plasminogen activator inhibitor-1 (PAI-1) is independently associated with NAFLD after adjustment for leptin and adiponectin levels [39]. This evidence concerns the gene SERPINE1 and metabolic dysfunction-associated steatotic liver disease.